CLINICAL TRIALS PROFILE FOR RETROVIR

All Clinical Trials for RETROVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000662 ↗	A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease	Completed	Glaxo Wellcome	N/A	1969-12-31	To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.
NCT00000662 ↗	A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.
NCT00000716 ↗	A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24 weeks to children between 3 months and 12 years of age. The effectiveness of AZT in treating HIV infection in infants and children will also be evaluated. HIV infection in children is most often associated with symptomatic disease and poor prognosis. Treatment with antiviral therapy may be effective in altering the course of the disease and decreasing mortality in these children. AZT has been shown to be effective in certain adult patients with symptomatic HIV infection. It is therefore likely that infected children may also benefit from this treatment.
NCT00002020 ↗	Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC	Completed	Glaxo Wellcome	N/A	1969-12-31	To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.

Clinical Trial Conditions for RETROVIR

Condition Name

Condition Name for RETROVIR
Intervention	Trials
HIV Infections	36
HIV	4
Healthy	2
Lymphoma	2

Condition MeSH

Condition MeSH for RETROVIR
Intervention	Trials
HIV Infections	38
Acquired Immunodeficiency Syndrome	19
Infections	12
Infection	11

Clinical Trial Locations for RETROVIR

Trials by Country

Trials by Country for RETROVIR
Location	Trials
United States	139
South Africa	11
Brazil	6
Puerto Rico	6
Uganda	5

Trials by US State

Trials by US State for RETROVIR
Location	Trials
Texas	12
Florida	11
California	11
North Carolina	11
New York	9

Clinical Trial Progress for RETROVIR

Clinical Trial Phase

Clinical Trial Phase for RETROVIR
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for RETROVIR
Clinical Trial Phase	Trials
Completed	45
Terminated	2
Recruiting	1

Clinical Trial Sponsors for RETROVIR

Sponsor Name

Sponsor Name for RETROVIR
Sponsor	Trials
Glaxo Wellcome	15
National Institute of Allergy and Infectious Diseases (NIAID)	11
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	6

Sponsor Type

Sponsor Type for RETROVIR
Sponsor	Trials
Industry	30
NIH	25
Other	17